评论
打印
The CEO of the pharmaceutical company that makes the life-saving EpiPen strongly defended the product's huge price hike on Capitol Hill on Wednesday. Mylan's Heather Bresch testified under oath in front of the House Oversight and Government Reform Committee, where lawmakers piled on criticism about the injector's nearly-500 percent price increase.
周三，生产急救药肾上腺素笔（EpiPen）的制药公司首席执行官在美国国会为该产品的高价强烈辩护。迈兰公司的希瑟·布莱什在众议院监管和政府改革委员会面前宣誓作证，立法者对该注射笔近500%的价格上涨表达了不满。
The hearing lasted well into the evening. Bresch said she wished Mylan had “better anticipated” the problems patients would face, as the company ratcheted up the cost of the device that stops life-threatening allergic reactions. CBS News reviewed documents the company turned over to lawmakers.
听证会一直持续到晚上。布莱什称她希望迈兰公司“最好已经预测到”病人们即将面临的问题，因为该公司逐渐提高了治疗威胁生命的过敏反应的设备花费。哥伦比亚广播公司查看了米兰公司交给立法者的文件。
They show Mylan expects the EpiPen to generate $1.1 billion in net sales this year. It spends an estimated $85 million to market the device. Bresch claimed her own salary last year was $18m.
他们表明迈兰公司希望肾上腺素注射笔今年的净销售额能达到11亿美元。让该设备上市大概要花费8500万美元。布莱什称她上个月的工资是1800万美元。
译文属可可英语创，未经允许，不得转载。
